Evidence map›Paper›PMID 36069557›Full record

ArticleJournal of clinical microbiology2022

Effective Rapid Diagnosis of Bacterial and Fungal Bloodstream Infections by T2 Magnetic Resonance Technology in the Pediatric Population.

Barbara Lucignano, Valeria Cento, Marilena Agosta, Federico Ambrogi, Sami Albitar-Nehme, Livia Mancinelli, Giordana Mattana, Manuela Onori, Federica Galaverna, Luca Di Chiara and 14 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07590648 (Phase IV, Randomized, Open Label, Parallel Groups Clinical Trial for Evaluating the Early Stop of Antibiotic Treatment in High-risk Febrile Neutropenic Oncohaematological Paediatric Patients), which is not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07590648 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Phase IV, Randomized, Open Label, Parallel Groups Clinical Trial for Evaluating the Early Stop of Antibiotic Treatment in High-risk Febrile Neutropenic Oncohaematological Paediatric Patients (e-STOP 2)

TypeinterventionalSponsorHospital Universitari Vall d'Hebron Research InstituteRan2026 to 2028Enrolled136ConditionsFebrile Neutropenia (FN), Pediatric Cancer, Hematologic Malignancies, Solid TumorsArmsEarly Discontinuation of Antibiotics, Standard Antibiotic Continuation Strategy
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 30 citations in OpenAlex.

  1. Persistent Non-Journal of fungi (Basel, Switzerland) · 2026
    Article
  2. [Requirements for the rational use of antibiotics based on antibiotic stewardship].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Evaluation of T2 Magnetic Resonance (T2MRAntibiotics (Basel, Switzerland) · 2024
    Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 1 country.

Barbara Lucignano *Unit of Microbiology and Diagnostic Immunology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Valeria Cento *Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Marilena AgostaUnit of Microbiology and Diagnostic Immunology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.ORCID 0000-0002-6017-3232
Federico AmbrogiDepartment of Clinical and Community Sciences, Università degli Studi di Milano, Milan, Italy.
Sami Albitar-NehmeUnit of Microbiology and Diagnostic Immunology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.ORCID 0000-0002-6472-5380
Livia MancinelliUnit of Microbiology and Diagnostic Immunology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Giordana MattanaUnit of Microbiology and Diagnostic Immunology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Manuela OnoriUnit of Microbiology and Diagnostic Immunology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Federica GalavernaDepartment of Pediatric Hematology and Oncology and of Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Luca Di ChiaraDepartment of Cardiology and Cardiac Surgery, Pediatric Cardiac Intensive Care Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Tiziana FragassoDepartment of Cardiology and Cardiac Surgery, Pediatric Cardiac Intensive Care Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Roberto BianchiAnesthesia and Critical Care Medicine, ARCO Rome, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Francesca TortoraAnesthesia and Critical Care Medicine, ARCO Rome, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Cinzia AuritiNeonatal Intensive Care Unit, Medical and Surgical Department of the Fetus Newborn and Infant, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.ORCID 0000-0001-9820-6557
Andrea DottaNeonatal Intensive Care Unit, Medical and Surgical Department of the Fetus Newborn and Infant, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Corrado CecchettiPediatric Intensive Care Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Salvatore PerdichizziPediatric Intensive Care Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Massimiliano RaponiHealth Directorate, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Andrea Onetti MudaDepartment of Laboratories, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Silvia Nerini MolteniChemical-Clinical and Microbiological Analysis, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Alberto VillaniGeneral Pediatrics Unit, Pediatric Emergency and General Pediatrics Department, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Franco LocatelliDepartment of Pediatric Hematology and Oncology and of Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Carlo Federico PernoUnit of Microbiology and Diagnostic Immunology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.ORCID 0000-0002-0825-5388
Paola BernaschiUnit of Microbiology and Diagnostic Immunology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Bambino Gesù Children's Hospital · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITHumanitas University · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Children are prone to bloodstream infections (BSIs), the rapid and accurate diagnosis of which is an unmet clinical need. The T2MR technology is a direct molecular assay for identification of BSI pathogens, which can help to overcome the limits of blood culture (BC) such as diagnostic accuracy, blood volumes required, and turnaround time. We analyzed results obtained with the T2Bacteria (648) and T2Candida (106) panels in pediatric patients of the Bambino Gesù Children's Hospital between May 2018 and September 2020 in order to evaluate the performance of the T2Dx instrument with respect to BC. T2Bacteria and T2Candida panels showed 84.2% and 100% sensitivity with 85.9% and 94.1% specificity, respectively. The sensitivity and specificity of the T2Bacteria panel increased to 94.9% and 98.7%, respectively, when BC was negative but other laboratory data supported the molecular result. T2Bacteria sensitivity was 100% with blood volumes <2 mL in neonates and infants. T2Bacteria and T2Candida provided definitive microorganism identification in a mean time of 4.4 and 3.7 h, respectively, versus 65.7 and 125.5 h for BCs (

Indexed as

MycosesSepsisBacteriaBlood CultureChildHumansInfant, NewbornMagnetic Resonance SpectroscopyTechnologybloodstream infectionsmolecular diagnosispediatric populationT2 magnetic resonanceT2 panels

Identifiers

PMID36069557
PMCPMC9580347
OpenAlexW4295980677

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.